APA (7th ed.) Citation

AM, D., J, W., F, D., MJ, H., M, C., GE, I., . . . E, V. (2026). Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: A phase 1b/2 trial. Nature medicine, 32(3), 1002. https://doi.org/10.1038/s41591-025-04182-9

Chicago Style (17th ed.) Citation

AM, D'Alise, et al. "Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers: A Phase 1b/2 Trial." Nature Medicine 32, no. 3 (2026): 1002. https://doi.org/10.1038/s41591-025-04182-9.

MLA (9th ed.) Citation

AM, D'Alise, et al. "Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers: A Phase 1b/2 Trial." Nature Medicine, vol. 32, no. 3, 2026, p. 1002, https://doi.org/10.1038/s41591-025-04182-9.